Abstract
Over the past few decades, a number of coronary artery disease (CAD) and cardiovascular disease (CVD) risk factors have been identified. The predictive power of “conventional” risk factors have been validated by observational, prospective and intervention studies. Nevertheless, all attempts to exactly predict the individual risk for CAD have failed, biased by a large number of incorrectly risk-classified subjects. To improve cardiovascular (CV) risk prediction, a large number of genetic and/or non-genetic biomarkers have been discovered and tested against the “classical” risk factors for their power to predict CV risk. Only few of them had a significant improvement over the predictive models. In this paper, the most investigated biomarkers will be discussed and the evidence of their use as predictors of CV will be questioned.
Similar content being viewed by others
References
Wilson PW, D’Agostino RB, Levy D et al (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847
Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003
Hippisley-Cox J, Coupland C, Vinogradova Y et al (2007) Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 335:136
Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C, Humphrey LL (2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 151:496–507
Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker RA, Woodcock J, Zeger SL (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
Biasillo G, Leo M, Della Bona R, Biasucci LM (2010) Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med 5(3):225–233
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98(8):731–733
Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Kastelein JJ, Khaw KT (2006) C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993–2003. Atherosclerosis 187(2):415–422
Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK (2002) C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 144(2):233–238
Bisoendial RJ, Kastelein JJ, Stroes ES (2007) C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 195(2):e10–e18
Lagrand WK, Niessen HW, Wolbink GJ et al (1997) C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95(1):97–103
Torzewski M, Torzewski DE, Bowyer et al (1998) C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18(9):1386–1392
Chang MK, Binder CJ, Torzewski M, Witztum JL (2002) C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99(20):13043–13048
Burke AP, Tracy RP, Kolodgie F et al (2002) Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 105(17):2019–2023
Mora S, Ridker PM (2006) Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)–can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 97(2A):33A–41A
Norata GD, Garlanda C, Catapano AL (2010) The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 20(2):35–40
Sprague AH, Khalil RA (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78(6):539–552
Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, Gullestad L, Damås JK (2008) Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 28(11):1909–1919
Hung MJ, Cheng WJ, Cheng CW, Li LF (2006) Comparison of serum levels of inflammatory markers in patients with coronary vasospasm without significant fixed coronary artery disease versus patients with stable angina pectoris and acute coronary syndromes with significant fixed coronary artery disease. Am J Cardiol 97(10):1429–1434
Hojo Y, Ikeda U, Takahashi M, Shimada K (2002) Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis 161(2):403–408
Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR (2002) Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 39(12):1917–1923
Noto D, Cottone S, Baldassare Cefalù A, Vadalà A, Barbagallo CM, Rizzo M, Pernice V, Minà M, Fayer F, Cerasola G, Notarbartolo A, Rocco Averna M (2007) Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thromb Haemost 98(6):1362–1367
Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736–741
Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bo¨hm M (2004) Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94(4):534–541
Yanes LL, Romero DG, Cucchiarelli VE, Fortepiani LA, Gomez-Sanchez CE, Santacruz F (2005) Role of endothelin in mediating postmenopausal hypertension in a rat model. Am J Physiol Regul Integr Comp Physiol 288(1):R229–R233
Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD (2003) Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 90:377–384
Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C (2009) The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54(8):669–677
de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald E (2007) Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 50(22):2117–2124
Mulvihill N, Foley J, Murphy R, Crean P, Walsh M (2000) Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 36:1210–1216
Blankenberg S, Rupprecht H, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J (2001) Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104:1336–1342
Rallidis L, Gika H, Zolindaki M, Xydas TA, Paravolidakis KE, Velissaridou AH (2003) Usefulness of elevated levels of soluble vascular cell adhesion molecule-1 in predicting in-hospital prognosis in patients with unstable angina pectoris. Am J Cardiol 92:1195–1197
Lin L, Park S, Lakatta EG (2009) RAGE signaling in inflammation and arterial aging. Front Biosci 1(14):1403–1413
Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH (2009) Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 132(1):96–101
Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D’Angelo A (2006) High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc 54:1149–1150
Palazzuoli A, Antonelli G, Quatrini I, Nuti R (2011) Natriuretic peptides in heart failure: where we are, where we are going. Int Emerg Med 6(1):63–68
Nishikimi T, Kuwahara K, Nakao K (2011) Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 57(2):131–140
Doi Y, Ninomiya T, Hata J, Hata J, Hirakawa Y, Mukai N, Mukai N, Mukai N, Ikeda F, Fukuhara M, Iwase M, Kiyohara Y, Kiyohara Y (2011) N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama Study. Arterioscler Thromb Vasc Biol 31(12):2997–3003
Rodseth RN, Lurati Buse GA, Bolliger D, Burkhart CS, Cuthbertson BH, Gibson SC, Mahla E, Leibowitz DW, Biccard BM (2011) The predictive ability of pre-operative B-type natriuretic peptide in vascular patients for major adverse cardiac events: an individual patient data meta-analysis. J Am Coll Cardiol 58(5):522–529
Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O (2005) Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48(1):156–163
Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355(25):2631–2639
Cushman M, Arnold AM, Psaty BM et al (2005) C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. Circulation 112:25–31
Lloyd-Jones DM, Nam BH, D’Agostino RB, Levy D, Murabito JM, Wang TJ et al (2004) Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA 291:2204–2211
Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG et al (2005) Whole-genome patterns of common DNA variation in three human populations. Science 307:1072–1079
McPherson R, Pertsemlidis A, Kavaslar N, Stewart AFR, Roberts R, Cox DR et al (2007) A common allele on chromosome 9 associated with coronary heart disease. Science 316:1488–1491
Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A et al (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316:1491–1493
Palomaki GE, Melillo S, Bradley LA (2010) Association between 9p21 genomic markers and heart disease: a meta-analysis. JAMA 303:648–656
Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H et al (2008) Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet 17:2320–2328
Chen Z, Qian Q, Ma G, Wang J, Zhang X, Feng Y et al (2009) A common variant on chromosome 9p21 affects the risk of early-onset coronary artery disease. Mol Biol Rep 36:889–893
Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H et al (2008) Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet 17:2320–2328
Pasmant E, Laurendeau I, He′ ron D, Vidaud M, Vidaud D, Bie` che I (2007) Characterization of a germline deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67:3963–3969
Patel RS, Su S, Neeland IJ, Ahuja A, Veledar E, Zhao J et al (2010) The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. Eur Heart J 31:3017–3023
Ardissino D, Berzuini C, Merlini PA, Mannucci MP, Surti A, Burtt N et al (2011) Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction. J Am Coll Cardiol 58:426–434
Anderson JL, Horne BD, Kolek MJ, Muhlestein JB, Mower CP, Park JJ et al (2008) Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. Am Heart J 156:1155–1162
Dandona S, Stewart AFR, Roberts R (2010) Genomics in coronary artery disease: past, present and future. Can J Cardiol 26(Suppl A):56A–59A
Preuss M, König IR, Thompson JR, Erdmann J, Absher D, Assimes TL et al and on behalf of the CARDIoGRAM Consortium. Design of the coronary ARtery disease genome-wide replication and meta-analysis (CARDIoGRAM) study: a genome-wide association meta-analysis involving more than 22,000 cases and 60,000 controls. Circ Cardiovasc Genet. 2010;3:475–483
Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H et al (2011) Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43:333–338
Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN et al (2011) Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 377:383–392
Paynter NP, Chasman DI, Pare′ G, Buring J, Cook NR, Miletich JP, Ridker PM (2010) Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 303:631–637
Davies RW, Dandona S, Stewart AFR, Chen L, Ellis S, Tang WH et al (2010) Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet 3:468–474
Talmud PJ, Cooper JA, Palmen J, Lovering R, Drenos F, Hingorani AD, Humphries SE (2008) Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem 54:467–474
Roberts R, Stewart A (2012) 9p21 and the genetic revolution for coronary artery disease. Clin Chem 58:104–112
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Averna, M., Noto, D. Clinical utility of novel biomarkers for cardiovascular disease risk stratification. Intern Emerg Med 7 (Suppl 3), 263–270 (2012). https://doi.org/10.1007/s11739-012-0830-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-012-0830-9